Arcutis Biotherapeutics (ARQT) said Sunday its preliminary fiscal Q4 revenue is expected to increase by about 366% to $63 million, driven by the demand for Zoryve, a skin disease treatment.

Analysts surveyed by FactSet expect revenue of $56.5 million.

Meanwhile, full-year product revenue is expected to be about $160 million, up by about 449% from a year earlier.

As of Dec. 31, preliminary cash, cash equivalents, restricted cash and marketable securities are expected to be about $229 million.

The company is set to report its fiscal Q4 results on Feb. 25.